# OnCo record paper-zhou-minerva-prime-evidence-nat-commun-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-zhou-minerva-prime-evidence-nat-commun-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-zhou-minerva-prime-evidence-nat-commun-2026" ;
  schema:name "Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer"@en ;
  schema:description "In the EVIDENCE trial of resected EGFR-mutated lung cancer, a blood test for leftover cancer picked out patients at higher risk of relapse, and icotinib helped whether or not it was positive."@en ;
  schema:url <https://onco.cc/key-papers/paper-zhou-minerva-prime-evidence-nat-commun-2026/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41467-026-76392-9>, <https://pubmed.ncbi.nlm.nih.gov/42706268/> ;
  schema:sameAs <https://doi.org/10.1038/s41467-026-76392-9> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Zhou F, Su C, Liang W, et al." ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/> ;
  onco:drugs <https://onco.cc/drugs/minerva-prime/>, <https://onco.cc/drugs/icotinib/> ;
  onco:companies <https://onco.cc/companies/genecast/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> ;
  onco:journals <https://onco.cc/journals/nature-communications/> .